A German biotech company has completed a pivotal clinical trial testing whether a personalized cell therapy can teach the immune system to accept a transplanted kidney without requiring lifelong immunosuppressive medications. The therapy, called MIC-Lx, represents a fundamentally different approach to transplantation, one that aims to induce immune tolerance rather than simply suppress the entire immune system.

Why Is Lifelong Immunosuppression Such a Burden for Transplant Patients?

Kidney transplantation saves lives, but it comes with a significant cost. After receiving a donor organ, patients must take immunosuppressive drugs for the rest of their lives to prevent their immune system from attacking and rejecting the transplant. These medications work by dampening the entire immune response, which leaves patients vulnerable to infections, exposes them to long-term toxicity, and creates a major treatment burden that affects quality of life.

MIC-Lx takes a different approach. Instead of suppressing immunity broadly, the therapy is designed to teach the immune system to specifically accept the donor organ while preserving its ability to fight infections and protect against disease. This targeted tolerance could eliminate or dramatically reduce the need for lifelong immunosuppression.

What Happened in the TOL-2 Trial?

TolerogenixX, a clinical-stage biopharmaceutical company based in Heidelberg, Germany, announced on June 29, 2026, that the last patient has undergone kidney transplantation in the TOL-2 trial, a randomized, controlled Phase IIb study evaluating MIC-Lx in living-donor kidney transplantation. All 63 donor-recipient pairs were enrolled and treated according to protocol across multiple clinical centers.

In the trial, patients were randomly assigned to one of two groups. A total of 42 patients received MIC-Lx in addition to standard immunosuppression, while 21 patients received standard immunosuppression alone as a control. The primary goal is to measure whether MIC-Lx recipients can achieve what researchers call an "operational tolerance-like phenotype" by day 367 following therapy administration.

How Does MIC-Lx Actually Work?

MIC-Lx is manufactured from donor-derived immune cells obtained through a process called leukapheresis, in which blood is drawn and specific immune cells are isolated. These cells are then modified using TolerogenixX's proprietary MIC (modified immune cells) technology. The customized therapy is administered intravenously to transplant recipients before the transplant surgery takes place.

What makes this approach unique is its speed and scalability. The entire manufacturing process takes approximately 24 hours, and because it follows a standardized procedure, it can be scaled up and made available globally. This is a significant advantage over other cell therapies that may require weeks of manufacturing time.

What Evidence Supports This Approach?

The TOL-2 trial builds on findings from an earlier Phase Ib trial called TOL-1. In that smaller study, kidney transplant recipients treated with MIC-Lx showed long-term donor-specific immune tolerance signals, preserved graft function, and reduced use of conventional immunosuppressive medication. These encouraging results provided the foundation for the larger Phase IIb trial now being completed.

"The completion of the last patient transplant in TOL-2 puts TolerogenixX on a clear pathway towards one of the most important clinical readouts in immune tolerance," said Prof. Dr. Matthias Schaier, CEO of TolerogenixX. "With all 63 donor-recipient pairs treated according to protocol, we believe MIC-Lx has the potential to transform transplant immunotherapy."

Prof. Dr. Matthias Schaier, CEO of TolerogenixX

What Are the Key Endpoints Being Measured?

The primary endpoint of the TOL-2 trial assesses whether patients achieve an operational tolerance-like phenotype at day 367 following MIC-Lx administration. This endpoint measures several important outcomes:

• Absence of Rejection: No biopsy-proven acute rejection, graft loss, graft dysfunction, or death
• Absence of Antibodies: No de novo donor-specific HLA antibodies, which are a sign the immune system is attacking the transplant
• Patient-Relevant Infections: Secondary endpoints track infection rates, graft function, and additional immunological parameters

All patients in the TOL-2 study will continue to be followed according to protocol, including a 12-month primary observation period and subsequent long-term follow-up.

When Will Results Be Available?

TolerogenixX plans to publish topline efficacy and safety data from the TOL-2 trial in the first half of 2027. This timeline means that preliminary results should become available within the next several months, providing the first real-world evidence of whether MIC-Lx can deliver on its promise of inducing immune tolerance in a larger, randomized patient population.

What Is the Broader Vision for This Technology?

While the current focus is on living-donor kidney transplantation, TolerogenixX is developing MIC-Lx as a potential immune tolerance platform for additional transplant settings and selected autoimmune diseases. The company has specifically mentioned plans to explore the therapy in systemic lupus erythematosus and multiple sclerosis, two serious autoimmune conditions in which the immune system mistakenly attacks the body's own tissues.

"TOL-2 was designed to test whether MIC-Lx can reproduce the donor-specific immune tolerance signals observed in TOL-1 within a randomized, controlled Phase IIb setting," explained Prof. Dr. Christian Morath, Chief Scientific Officer of TolerogenixX. "This study addresses one of the key challenges in kidney transplantation, reducing the burden of lifelong immunosuppression without compromising graft protection."

Prof. Dr. Christian Morath, Chief Scientific Officer of TolerogenixX

Why Does This Matter for Patients?

If MIC-Lx proves effective in the TOL-2 trial, it could fundamentally change the transplant experience for millions of people worldwide. Reducing or eliminating the need for lifelong immunosuppression would mean fewer infections, less long-term organ damage from toxic medications, improved quality of life, and potentially better long-term graft survival. For autoimmune disease patients, a similar approach could offer a way to restore immune tolerance without the broad immunosuppression that comes with current treatments.

The completion of patient enrollment in TOL-2 represents a critical milestone in the development of personalized cell therapies for immune-mediated diseases. As the field moves toward the 2027 data readout, transplant patients and those living with autoimmune conditions are watching closely to see whether this novel approach can deliver on its transformative potential.